Clinical trial · Interventional
Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer
Markers of the Inflammatory Response (IL-1β, IL-10, IL-17A and TNF-α) in Patients With Colorectal Cancer in Chemotherapy Supplemented With Fish Oil
NCT01575340CI-TRIAL-00007954completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate whether supplementation 2g/day encapsulated fish oil modifies inflammatory markers in individuals with colorectal cancer in chemotherapy
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Inflammation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| fish oil encapsuled | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- fish oil encapsuled
- description
- will receive the supplementation of 2 g / day of fish oil encapsulated for 9 weeks
- interventionNames
- Dietary Supplement: fish oil encapsuled
- type
- NO_INTERVENTION
- label
- without supplementation
- description
- not will receive supplementation or encapsulated fish oil or placebo
Primary outcomes (1)
- measure
- change in inflammatory markers
- timeFrame
- two months
- description
- will be evaluated cytokines IL-1 beta, IL-10, IL-17A and TNF alpha, and acute phase proteins CRP and Albumin, in baseline that corresponds to the day that the patient will begin chemotherapy and the final moment, which corresponds to 9 weeks counting from the baseline in both groups (supplemented and non-supplemented)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 19 years * Histopathological diagnosis of colorectal cancer * Beginning of chemotherapy in the target institution * Agree to participate in the study \[signature of IC\] Exclusion Criteria: * Age \<19 years * Being in palliative care * Inability to oral intake * Allergic to the fish and fish products * Owning with hyperlipidemia requiring drug treatment * Consumption prior to the study of fish oil or supplements containing omega-3 PUFA * Being in medical treatment with some nonsteroidal anti-inflammatory * Have some kind of infection
References
Publications (0)
Data not yet available
No reference posted for this study.